Gapping up
In reaction to earnings/guidance:
- SHEN +20.8% (guidance; will issue a special dividend of $18.75/share), MTOR +18.9% (also awarded new business to produce electric powertrains), EVR +11.6%, ATGE +8.5%, AMCR +8.4%, GOOG +7.4%, SNE +6.9%, CPRI +6.7%, VCYT +6.3% (also acquires Decipher Biosciences), VIAV +6.2%, VNE +5.4%, VOD +4.8%, INGR +4.3%, LU +4.2%, WNC +4.2%, ICHR +3.6%, SCSC +3.5%, DT +3.5%, NMR +3.2%, APO +3.1%, BDN +3%, APAM +3% (also announces $0.31/sh special dividend), NVO +3%, LGND +2.8%, TCS +2.7%, DOX +2.7% (also announces service agreements with various partners), AVY +2.6%, AMZN +2.5% (also Jeff Bezos will transition to Exec Chair in Q3; Andy Jassy will then become CEO), SMG +2.3%, SLAB +2.3%, POWI +2.2%, CHKP +1.8%, GL +1.5%, ABBV +1.5%, MANH +1.4%, HUM +1.4%, TGI +1.3%, LFUS +1%, .
M&A news:
- VCVC +39.9% (10X Capital Venture Acquisition Corp: REE Automotive to list on NASDAQ through merger with 10X Capital Venture Acquisition Corp)
- RUHN +9.2% (enters into merger agreement with RUNION in transaction with equity value of ~$296.4 mln)
- INFU +4.1% (has acquired FilAMed, a privately held biomedical services company)
- GWPH +2.6% (GW Pharma agrees to be acquired by Jazz Pharmaceuticals (JAZZ) for $220.00 per ADS in cash and shares) .
Other news:
- LIZI +26% (releases letter to shareholders from CEO Jinnan Lai)
- CLIR +17.5% (receives purchase order from global refining co)
- ISBC +10.6% (to be added to S&P SmallCap 600)
- BCRX +8.5% (announces that the U.S. Food and Drug Administration has approved a supplemental new drug application for RAPIVAB expanding the patient population of RAPIVAB for the treatment of acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days)
- CDMO +7.6% (Avid Bioservices and Humanigen (HGEN) entered into manufacturing agreement to expand production capacity for lenzilumab, Humanigen's therapeutic candidate in development for COVID-19)
- SNE +7% (promotes Neal Manowitz to COO of Sony Electronics Inc North America)
- ARGX +6.3% (prices offering of 1,608,000 ADSs at a price of $320.00 per ADS and the sale of 1,517,000 ordinary shares at a price of €265.69 per ordinary share)
- CVAC +6.1% (CureVac and GlaxoSmithKline to develop next generation mRNA COVID-19 vaccines)
- AFMD +3.9% (entered into a clinical research collaboration with Roche (RHHBY) to explore the combination of Affimed's innate cell engager AFM24 with Roche's PD-L1 checkpoint inhibitor atezolizumab)
- BZUN +3.1% (entered into a share purchase agreement with all the shareholders of Full Jet Limited to acquire a 100% equity interest in Full Jet)
- TCON +2.9% (new CFO)
- ARQT +1.9% (prices 5.5 mln shares of common stock at $35.00 per share)
- VUZI +1.6% (files for $300 mln mixed securities shelf offering)
- CX +1.4% (announces efforts to optimize supply chain)
- UGI +1.4% (announces partnership with Ekobenz)
- FCX +1.4% (reinstates dividend)
Analyst comments:
- TTI +5.7% (upgraded to Buy from Hold at Stifel)
- KSS +1.7% (upgraded to Outperform from Market Perform at Cowen)
- NUE +1.6% (upgraded to Outperform from Neutral at Credit Suisse)
- NXPI +1.6% (upgraded to Outperform from Perform at Oppenheimer)
- ATHM +1.1% (upgraded to Buy from Hold at The Benchmark Company)